Edition:
United States

People: Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

20.50USD
7 Dec 2016
Change (% chg)

$-1.15 (-5.31%)
Prev Close
$21.65
Open
$21.20
Day's High
$21.50
Day's Low
$20.00
Volume
508,108
Avg. Vol
603,780
52-wk High
$43.63
52-wk Low
$16.40

Hindman, Andrew 

Mr. Andrew Hindman is Chief Business Development Officer of the Company. Mr. Hindman has held several senior executive level positions in the biopharmaceutical industry, most recently as President, Chief Executive Officer and member of the Board of Tobira Therapeutics, a privately-held biotechnology company. At Tobira, he was responsible for developing a new corporate strategy, building new leadership and operational teams, and raising operating capital. Prior to Tobira, he held senior corporate development and commercial operating positions at Nodality, Onyx Pharmaceuticals and Gilead Sciences. Mr. Hindman holds a B.A. in biochemistry and economics, graduating Phi Beta Kappa from Wesleyan University, and an executive MBA from Columbia University and the University of California Berkeley, Haas School of Business.

Basic Compensation

Total Annual Compensation, USD 476,986
Restricted Stock Awards, USD 1,685,520
Long-Term Incentive Plans, USD --
All Other, USD 3,005,160
Fiscal Year Total, USD 5,167,670

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ron Cohen

4,045,180

David Lawrence

1,204,120

Andrew Blight

1,484,560

Jane Wasman

2,334,280

Burkhard Blank

--

Andrew Hindman

5,167,670
As Of  30 Dec 2014